OMNIBUS AMENDMENT NO. 1 TO INDENTURE AND LETTER OF CREDITIndenture and Letter • July 21st, 2022 • Vickers Vantage Corp. I • Biological products, (no disgnostic substances) • New York
Contract Type FiledJuly 21st, 2022 Company Industry JurisdictionThis OMNIBUS AMENDMENT NO. 1 TO INDENTURE AND LETTER OF CREDIT, dated as of October 1, 2019 (this “Amendment”), is among SCILEX PHARMACEUTICALS INC., a Delaware corporation (the “Issuer”), SORRENTO THERAPEUTICS, INC., a Delaware corporation (the “Parent Guarantor”), U.S. BANK NATIONAL ASSOCIATION, as trustee (in such capacity, together with its successors and assigns in such capacity, the “Trustee”) and collateral agent (in such capacity, together with its successors and assigns in such capacity, the “Collateral Agent”) under the Indenture (as defined below), and the beneficial owners of the Securities and the Holders listed on the signature pages hereof (collectively, the “Holders”).